Tag: Anti cd20

Ocrevus (ocrelizumab) was the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for both relapsing and primary progressive forms of multiple sclerosis in adults. But what drug category is Ocrevus? It belongs to a class of highly specific, targeted immunotherapies known as anti-CD20 monoclonal antibodies, which selectively deplete certain immune cells believed to drive MS pathology.

Since its initial U.S. approval in 1997, rituximab has revolutionized the treatment of B-cell malignancies and autoimmune diseases [1.5.1, 1.12.3]. For patients and clinicians asking 'What is an alternative to rituximab?', a new generation of advanced therapies offers promising options with improved efficacy and novel mechanisms.